MARKETVUE® REPORT: Gene therapies for treatment of Glycogen Storage Disease Type 1a offer hope for overburdened patientsAmanda Theocles2023-09-28T15:14:46+00:00September 28th, 2023|Read More
Graves’ Disease patients face limited treatment options that do not irreversibly destroy the thyroid (MARKETVUE® REPORT)Amanda Theocles2023-09-12T13:59:07+00:00September 12th, 2023|Read More
Ophthalmologists estimate 10% of Geographic Atrophy patients are now treated with Syfovre since its February 2023 approval (MARKETVUE® REPORT)Amanda Theocles2023-09-12T13:53:49+00:00September 12th, 2023|Read More
Filspari and Tarpeyo launches off to a great start in IgAN (MARKETVUE® REPORT)Danielle Drayton2023-07-27T15:51:32+00:00July 27th, 2023|Read More
MARKETVUE® REPORT: Gene therapies for treatment of Glycogen Storage Disease Type 1a offer hope for overburdened patientsAmanda Theocles2023-09-28T15:14:46+00:00September 28th, 2023|Read More
Graves’ Disease patients face limited treatment options that do not irreversibly destroy the thyroid (MARKETVUE® REPORT)Amanda Theocles2023-09-12T13:59:07+00:00September 12th, 2023|Read More
Ophthalmologists estimate 10% of Geographic Atrophy patients are now treated with Syfovre since its February 2023 approval (MARKETVUE® REPORT)Amanda Theocles2023-09-12T13:53:49+00:00September 12th, 2023|Read More
Filspari and Tarpeyo launches off to a great start in IgAN (MARKETVUE® REPORT)Danielle Drayton2023-07-27T15:51:32+00:00July 27th, 2023|Read More
